Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 28;1(2):65-72.
doi: 10.1200/JGO.2015.000265. eCollection 2015 Dec.

Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance

Vijay M Patil  1 , Vanita Noronha  1 , Amit Joshi  1 , Vamshi Muddu  1 , Sachin Dhumal  1 , Atanu Bhattacharjee  1   2 , Kumar Prabhash  1
Affiliations

Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance

Vijay M Patil et al. J Glob Oncol. .

Abstract

Purpose: Approximately 15% to 20% of our patients with head and neck cancer receiving neoadjuvant chemotherapy (NACT) discontinue therapy because of various nonmedical reasons. We sought to analyze the factors associated with treatment default and noncompliance among these patients.

Patients and methods: We performed a retrospective analysis of patients with T4 oral cancer treated with NACT between January 2011 and December 2012. We included patients who discontinued treatment for nonmedical reasons before the second cycle of NACT. The factors analyzed were income, education, socioeconomic status, age, sex, place of residence, habits, and payment pattern (government supported or personal capacity). Pearson χ2 test was used to identify significant factors associated with noncompliance.

Results: Of 486 patients, 91 patients (18.7%) were noncompliant. Percentages of noncompliant patients in the age groups < 30, between 30 and 60, and > 60 years were 25.0%, 17.4%, and 25.5%, respectively (P = .27). Percentages of noncompliance in patients residing within the city, same state, or different state were 20.7%, 20.9%, and 17.1%, respectively (P = .44). Noncompliance rates were 20.3%, 15.7%, 18.1%, and 22.5% in upper middle, lower middle, upper lower, and lower economic strata, respectively (P = .60). Similarly, there was no significant difference in noncompliance according to occupation, education level, payment pattern, sex, or habits.

Conclusion: Our analysis failed to identify any specific significant factor associated with noncompliance with NACT among our patients with T4 oral cancers.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and contributions are found at the end of this article.The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Vijay M. PatilNo relationship to discloseVanita NoronhaNo relationship to discloseAmit JoshiNo relationship to discloseVamshi MudduHonoraria: Bristol-Myers SquibbSachin DhumalNo relationship to discloseAtanu BhattacharjeeNo relationship to discloseKumar PrabhashNo relationship to disclose

Figures

Figure 1
Figure 1
CONSORT diagram: patient selection criteria. NACT, neoadjuvant chemotherapy; PS-2, Eastern Cooperative Oncology Group performance status-2.
See this image and copyright information in PMC

References

    1. Pfister DG Ang KK Brizel DM, etal: Head and neck cancers, version 2.2013: Featured updates to the NCCN guidelines J Natl Compr Canc Netw 11:917–923,2013 - PubMed
    1. Grégoire V Lefebvre JL Licitra L, etal: Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21:v184–v186,2010suppl 5 - PubMed
    1. Rath GK Parikh PM Hukku S, etal: Indian Council of Medical Research consensus document for the management of buccal mucosa cancer Indian J Med Paediatr Oncol 35:136–139,2014 - PMC - PubMed
    1. Patil VM Prabhash K Noronha V, etal: Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers Oral Oncol 50:1000–1004,2014 - PubMed
    1. Haddad R O'Neill A Rabinowits G, etal: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial Lancet Oncol 14:257–264,2013 - PubMed